Soluble amyloid precursor proteins in cerebrospinal fluid as biomarkers of Alzheimer's disease

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent presents a method for diagnosing Alzheimer's disease by measuring the concentrations of two specific soluble forms of amyloid precursor protein—sAPPα and sAPPβ—in a patient's cerebrospinal fluid (CSF). By comparing these levels to defined threshold values, clinicians can determine the probability that a patient has or is at risk of developing Alzheimer's. The patent also covers kits and assays for performing this measurement, supporting accurate and early detection of Alzheimer's disease.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and accurate diagnosis of Alzheimer's disease in patients showing symptoms of dementia or mild cognitive impairment.
• Differential diagnosis to distinguish Alzheimer's disease from other forms of dementia.
• Retrospective analysis using stored CSF samples to monitor Alzheimer's progression or validate past diagnoses.
• Clinical research to identify at-risk individuals or track disease biomarkers over time.
• Supporting selection and monitoring of patients for clinical trials of Alzheimer's treatments.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a more objective, biomarker-based approach to Alzheimer's diagnosis, improving accuracy compared to clinical diagnosis alone.
• Allows for early detection of Alzheimer's, potentially before significant cognitive decline occurs.
• Soluble APP markers (sAPPα and sAPPβ) in CSF are stable across various storage conditions, enabling reliable tests even with stored or transported samples.
• High sensitivity and specificity can be achieved using the defined threshold values for sAPPα and sAPPβ.
• Multiplexed assay allows for efficient, simultaneous measurement of both biomarkers, conserving valuable CSF sample volume.
• Can be implemented with existing immunoassay technology, facilitating adoption in clinical and laboratory settings.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

An ex vivo method of diagnosing Alzheimer's disease comprising the steps of analysing a cerebrospinal fluid (CSF) sample taken from a patient with regard to a concentration of at least one amyloid precursor protein (APP) product selected from the group consisting of soluble forms of amyloid precursor protein ± and ² (sAPP± and sAPP²); comparing the concentration of the at least one APP product with a threshold-value for the concentration of the respective one APP product; and indicating a probability that the patient has or is prone to Alzheimer's disease, if the concentration of the at least one APP product exceeds the threshold-value for the concentration of the respective one APP product.